Volume 41 Issue 1, January 2023

New sequencers are poised to disrupt Illumina’s dominance. Users will need to navigate the opportunities and challenges on offer in an increasingly crowded market.

The November approval of Tzield (teplizumab) marks a turning point in the management of type 1 diabetes.

The regulator's nod is a first for lab-grown meat in the United States.

Many biomedical questions demand scalable, deep, and accurate proteome analysis of small samples, including single cells. A scalable framework of multiplexed data-independent acquisition for mass spectrometry enables time saving by parallel analysis of both peptide ions and protein samples, thereby realizing multiplicative gains in throughput.

Porcine dermal collagen was chemically and photochemically bioengineered into an implantable tissue mimicking the human corneal extracellular matrix. The implant presents a simpler and safer method than donor cornea transplantation while delivering equivalent outcomes, and has restored vision to people with advanced keratoconus in resource-limited regions, where the burden of blindness is highest.

Accurate identification and effective removal of unwanted variation is essential to derive meaningful biological results from large and complex RNA-seq studies. Technical replicates together with negative and positive control genes are key tools for carrying out this task. We show how to proceed when technical replicates are unavailable.

The application of CRISPR–Cas13 for targeted RNA degradation is hindered by the existence of collateral effects induced by Cas13. We screened hundreds of engineered Cas13 variants using a convenient and sensitive reporter system and obtained several variants with markedly reduced collateral activity and efficient on-target activity, suitable for in vivo applications.

This study reveals a high level of behavioral heterogeneity in engineered T cells that target tumor organoids. Behavior-guided transcriptomics identified the gene signatures of T cells with highly potent serial cytotoxicity. Integration of the organoid and T cell transcriptomic data enabled the design of patient-specific combinatorial treatment to achieve an optimized response to cancer immunotherapies.